Literature DB >> 6147851

Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.

S W Tam, L Cook.   

Abstract

The relationship between binding of antipsychotic drugs and sigma psychotomimetic opiates to binding sites for the sigma agonist (+)-[3H]SKF 10,047 (N-allylnormetazocine) and to dopamine D2 sites was investigated. In guinea pig brain membranes, (+)-[3H]SKF 10,047 bound to a single class of sites with a Kd of 4 X 10(-8) M and a Bmax of 333 fmol/mg of protein. This binding was different from mu, kappa, or delta opiate receptor binding. It was inhibited by opiates that produce psychotomimetic activities but not by opiates that lack such activities. Some antipsychotic drugs inhibited (+)-[3H]SKF 10,047 binding with high to moderate affinities in the following order of potency: haloperidol greater than perphenazine greater than fluphenazine greater than acetophenazine greater than trifluoperazine greater than molindone greater than or equal to pimozide greater than or equal to thioridazine greater than or equal to chlorpromazine greater than or equal to triflupromazine. However, there were other antipsychotic drugs such as spiperone and clozapine that showed low affinity for the (+)-[3H]SKF 10,047 binding sites. Affinities of antipsychotic drugs for (+)-[3H]SKF 10,047 binding sites did not correlate with those for [3H]spiperone (dopamine D2) sites. [3H]-Haloperidol binding in whole brain membranes was also inhibited by the sigma opiates pentazocine, cyclazocine, and (+)-SKF 10,047. In the striatum, about half of the saturable [3H]haloperidol binding was to [3H]spiperone (D2) sites and the other half was to sites similar to (+)-[3H]SKF 10,047 binding sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147851      PMCID: PMC391758          DOI: 10.1073/pnas.81.17.5618

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  11 in total

1.  Neuroleptic activity of the neuropeptide beta-LPH62-77 ([Des-Tyr1]gamma-endorphin; DT gamma E).

Authors:  D De Wied; G L Kovács; B Bohus; J M Van Ree; H M Greven
Journal:  Eur J Pharmacol       Date:  1978-06-15       Impact factor: 4.432

2.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

3.  Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI).

Authors:  C A Haertzen
Journal:  Psychopharmacologia       Date:  1970

Review 4.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

5.  Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites.

Authors:  R S Zukin; S R Zukin
Journal:  Mol Pharmacol       Date:  1981-09       Impact factor: 4.436

6.  Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain.

Authors:  T P Su
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

7.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

8.  Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog.

Authors:  D B Vaupel
Journal:  Eur J Pharmacol       Date:  1983-09-02       Impact factor: 4.432

9.  Naloxone-inaccessible sigma receptor in rat central nervous system.

Authors:  S W Tam
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

10.  Antinociceptive studies of the optical isomers of N-allylnormetazocine (SKF 10,047).

Authors:  M D Aceto; E L May
Journal:  Eur J Pharmacol       Date:  1983-07-22       Impact factor: 4.432

View more
  59 in total

1.  Pregnancy reduces brain sigma receptor function.

Authors:  R Bergeron; C de Montigny; G Debonnel
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  A new method for evaluating sigma(2) ligand activity in the isolated guinea-pig bladder.

Authors:  Nicola A Colabufo; Francesco Berardi; Marialessandra Contino; Roberto Perrone; Vincenzo Tortorella
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-17       Impact factor: 3.000

3.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator.

Authors:  Tsung-Ping Su; Teruo Hayashi; Tangui Maurice; Shilpa Buch; Arnold E Ruoho
Journal:  Trends Pharmacol Sci       Date:  2010-10-01       Impact factor: 14.819

4.  Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays.

Authors:  Hideaki Yano; Alessandro Bonifazi; Min Xu; Daryl A Guthrie; Stephanie N Schneck; Ara M Abramyan; Andrew D Fant; W Conrad Hong; Amy H Newman; Lei Shi
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

5.  Inhibition of (+)[3H]SKF 10,047 binding to rat brain membranes by FAB fragments from a monoclonal antibody directed against the opioid receptor.

Authors:  C B Tyler; J M Bidlack
Journal:  Neurochem Res       Date:  1988-08       Impact factor: 3.996

6.  Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET.

Authors:  Nisha K Ramakrishnan; Anniek K D Visser; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2014-03-18       Impact factor: 4.530

7.  Intrathecal treatment with sigma1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice.

Authors:  Hyun-Woo Kim; Young-Bae Kwon; Dae-Hyun Roh; Seo-Yeon Yoon; Ho-Jae Han; Kee-Won Kim; Alvin J Beitz; Jang-Hern Lee
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

8.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

9.  The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents.

Authors:  L J Bristow; P H Hutson; L Thorn; M D Tricklebank
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

10.  Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors?

Authors:  C L Nilsson; E Eriksson
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.